Vasopressin and urinary concentrating activity in diabetes mellitus

Diabetes and Metabolism

Volumn 25, Issue 3, 1999, Pages 213-222

  Ahloulay, M ^b,e   Schmitt, F ^c   Dechaux M ^d   Bankir, L ^a,b  

^a INSERM   (France)

^b INSTITUT DU FER À MOULIN   (France)

^c Laboratoire de Biochimie Cellulaire   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e FACULTÉ DES SCIENCES   (Morocco)

Author keywords

Diabetes mellitus; Glomerular filtration rate; Glucagon; Glucose; Kidney hypertrophy; Solute excretion; Solute free water reabsorption; Streptozotocin; Vasopressin

Indexed keywords

GLUCOSE; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; GLUCOSE URINE LEVEL; KIDNEY CONCENTRATING CAPACITY; KIDNEY TUBULE ABSORPTION; MALE; NONHUMAN; RAT; STREPTOZOCIN DIABETES; URINE OSMOLALITY; VASOPRESSIN RELEASE; WATER ABSORPTION;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; DIURESIS; DRINKING BEHAVIOR; GLUCAGON; GLYCOSURIA; KIDNEY CONCENTRATING ABILITY; MALE; POTASSIUM; RATS; RATS, WISTAR; SODIUM; UREA; VASOPRESSINS;

EID: 0032837674     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Walsh CH, Baylis PH, Malins JM. Plasma arginine vasopressin in diabetic ketoacidosis. Diabetologia, 1979, 16, 93-96.
2. Zerbe RL, Vinicor F, Robertson GL. Plasma vasopressin in uncontrolled diabetes mellitus. Diabetes, 1979, 28, 503-508.
3. Fujisawa I, Murakami N, Furuto-Kato S, Araki N, Konishi J. Plasma and neurohypophyseal content of vasopressin in diabetes mellitus. J Clin Endocrinol Melab, 1996, 81, 2805-2809.
4. Van-Itallie CM, Fernstrom JD. Osmolal effects on vasopressin secretion in the streptozotocin-diabetic rat. Am J Physiol, 1982, 242 (Endocrinol. Metab. 5), E411-E417.
5. Brooks DP, Nutting DF, Crofton JT, Share L. Vasopressin in rats with genetic and streptozotocin-induced diabetes. Diabetes, 1989, 38, 54-57.
6. Tomlinson KC, Gardiner SM, Hebden RA, Bennet T. Functional consequences of streptozotocin-induced diabetes mellitus, with particular reference to the cardiovascular system. Physiol Reviews, 1992, 44, 103-150.
7. Zerbe RL, Vinicor F, Robertson GL. Regulation of plasma vasopressin in insulin-dependent diabetes mellitus. Am J Physiol, 1985, 249 (Endocrinol. Metab. 12), E317-E325.
8. Jensen PK, Christiansen JS, Steven K, Parving HH. Renal function in streptozotocin-diabetic rats. Diabetologia, 1981, 21, 409-414.
9. 2 receptors in diabetes mellitus. Am J Physiol, 1994, 266 (Endocrinol. Metab. 29), E217-E223.
10. Ikeda M, Yoshitomi K, Imai M, Kurokawa K. Cell Ca2 + response to luminal vasopressin in cortical collecting tubule principal cells. Kidney Int, 1994, 45, 811-816.
11. Barreto-Chaves MLM, De-Mello-Aires M. Luminal arginine vasopressin stimulates Na + -H + exchange and H + -ATPase in cortical distal tubule via V1 receptor. Kidney Int, 1997, 52, 1035-1041.
12. Jamil KMA, Watanabe T, Nakao A, Okuda T, Kurokawa K. Distinct mechanisms of actions of V7 antagonists OPC-21268 and [d(CH2)5Tyr(Me)AVP] in mesangial cells. Biochem Biophys Res Com, 1993, 193, 738-743.
13. Beck T, Dunn M. The relationship of antidiuretic hormone and renal prostaglandins. Miner Electrolyte Metab, 1981, 6, 46-59.
14. Park F, Mattson DL, Skelton MM, Cowley-Jr AW. Localization of the vasopressin V1a and V2 receptors within the renal cortical and medullary circulation. Am J Physiol, 1997, 273 (Regulatory Integrative Comp. Physiol. 42), R243-R251.
15. Ostrowski NL, Lolait SJ, Bradley DJ, O'Carroll AM, Brownstein MJ, Young WS. Distribution of V1a and V2 vasopressin receptor messenger ribonucleic acids in rat liver, kidney, pituitary and brain. Endocrinology, 1992, 131, 533-535.
16. Terada Y, Tomita K, Nonoguchi H, Yang T, Marumo F. Different localization and regulation of two types of vasopressin receptor messenger RNA in microdissected rat nephron segments using reverse transcription polymerase chain reaction. J Clin Invest, 1993, 92, 2339-2345.
17. Thibonnier M, Woloschak M. Platelet aggregation and vasopressin receptors in patients with diabetes mellitus. Proc Soc Exp Biol Med, 1988, 188, 2, 149-152.
18. 1a receptor mRNA in diabetes mellitus in the rat. Clin Sci, 1995, 88, 671-674.
19. Morel A, O'Carroll AM, Brownstein MJ, Lolait SJ. Molecular cloning and expression of a rat V1a arginine vasopressin receptor. Nature, 1992, 356, 523-526.
20. Whitton PD, Rodrigues LM, Hems DA. Stimulation by vasopressin, angiotensin and oxytocin of gluconeogenesis in hepatocyte suspensions. Biochem J, 1978, 176, 893-898.
21. Michell RH, Kirk CJ, Billah MM. Hormonal stimulation of phosphatidylinositol breakdown, with particular reference to hepatic effects of vasopressin. Biochem Soc Trans, 1979, 7, 861-865.
22. Martin G, Baverel G. Vasopressin promotes the metabolism of near-physiological concentration of glutamine in isolated rat liver cells. Bioscience Reports, 1984, 4, 171-176.
23. Drew PJT, Monson JP, Metcalfe HK, Evans SJW, Iles RA, Cohen RD. The effect of arginine vasopressin on ureagenesis in isolated rat hepatocytes. Clin Sci, 1985, 69, 231-233.
24. Keppens S, Vandekerckhove A, Moshage H, Yap SH, Aerts R, DeWulf H. Regulation of glycogen phosphorylase activity in isolated human hepatocytes. Hepatol, 1993, 17, 610-614.
25. Bardoux P, Martin H, Ahloulay M, et al. Vasopressin contributes to hyperfiltration and hypermetabolism in diabetes mellitus (abstract). J Am Soc Nephrol. 1997, 8, 634A-635A.
26. Elalouf JM, Sari DC, Rouffignac-de C. Additive effects of glucagon and vasopressin on renal Mg reabsorption and urine concentrating ability in the rat. Pflügers Arch, 1986, 407 (Supp 2), S 66-S 71.
27. Ahloulay M, Bouby N, Machet F, Kubrusly M, Coutaud C, Bankir L. Effects of glucagon on glomerular filtration rate and urea and water excretion. Am J Physiol, 1992, 263 (Renal Fluid Electrolyte Physiol. 32), F24-F36.
28. Unger RH, Orci L. The essential role of glucagon in the pathogenesis of diabetes mellitus. The Lancet, 1975, 4, 14-16.
29. Raskin P, Unger RH. Hyperglucagonemia and its suppression. Importance in the metabolic control of diabetes. N Engl J Med, 1978, 299, 433-436.
30. Bankir L, Kriz W. Adaptation of the kidney to protein intake and to urine concentrating activity: similar consequences in health and disease (Editorial Review). Kidney Int, 1995, 47, 7-24.
31. Bergström J, Ahlberg M, Alvestrand A. Influence of protein intake on renal hemodynamics and plasma hormone concentrations in normal subjects. Acta Med Scand, 1985, 217, 189-196.
32. Daniels BS, Hostetter TH. Effect of dietary protein intake on vasoactive hormones. Am J Physiol, 1990, 258 (Regulatory Integrative Comp. Physiol. 27), R1095-R1100.
33. Woods LL. Mechanisms of renal hemodynamic regulation in response to protein feeding. Kidney Int, 1993, 44, 659-675.
34. Bouby N, Ahloulay M, Nsegbe E, Déchaux M, Schmitt F, Bankir L. Vasopressin increases GFR in conscious rats through its antidiuretic action. J Am Soc Nephrol, 1996, 7, 842-851.
35. Bardoux P, Martin H, Schmitt F, Bouby N, Bankir L. Vasopressin increases urinary albumin excretion in normal rats and contributes to albuminuria of diabetes mellitus (abstract). J Am Soc Nephrol, 1998,
36. Bankir L, Ahloulay M, Bouby N, et al. Is the process of urinary urea concentration responsible for a high glomerular filtration rate? (Editorial Review). J Am Soc Nephrol, 1993, 4, 1091-1103.
37. Bouby N, Tring-Trang-Tan MM, Laouari D, et al. Role of the urinary concentrating process in the renal effects of high protein intake. Kidney Int, 1988, 43, 4-12.
38. Bouby N, Trinh-Trang-Tan MM, Coutaud C, Bankir L. Vasopressin is involved in the renal effects of high protein diet: study in homozygous Brattleboro rats. Am J Physiol, 1991, 260 (Renal Fluid Electrolyte Physiol. 29), F96-F100.
39. Bouby N, Bankir L. Role of urine concentration in the progression of renal failure. In: Gretz N, Strauch M, eds. "Experimental and genetic rat models of chronic renal failure". Basel:Karger, 1993, 216-225.
40. Bouby N, Bachmann S, Bichet D, Bankir L. Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol, 1990, 258 (Renal Fluid Electrolyte Physiol 27), F973-F979.
41. Okada H, Suzuki H, Kanno Y, Saruta T. Evidence for the involvement of vasopressin in the pathophysiology of adriamycin-induced nephropathy in rats. Nephron, 1996, 72, 667-672.
42. Nishikawa T, omura M, Tizuka T, Saito I, Yoshida S. Short-term clinical trial of 1-[1-(4-(3-acetylaminopropoxy)-benzoyl)-4-piperidyl]-3,4-dihydro-2(1H)- quinolinone in patients with diabetic nephropathy. Drug Res, 1996, 46, 875-878.
43. Zipser R, Myers S, Needleman P. Stimulation of renal prostaglandins synthesis by the pressor activity of vasopressin. Endocrinology, 1981, 108, 495-499.
44. Ledderhos C, Mattson DL, Skelton MM, Cowley-Jr AW. In vivo diuretic actions of renal vasopressin V1 receptor stimulation in rats. Am J Physiol, 1995, 268 (Regulatory Integrative Comp. Physiol. 37), R796-R807.
45. Mau-Pedersen M, Christiansen JS, Pedersen EB, Mogensen CE. Determinants of intra-individual variation in kidney function in normoalbuminuric insulin-dependent diabetic patients: importance of atrial natriuretic peptide and glycaemic control. Clin Sci, 1992, 83, 445-451.
46. Bardoux P, Martin H, Ahloulay M, Schmitt F, Bouby N, Trinh-Trang-Tan MM, Bankir L. Vasopressin contributes to hyperfiltration, albuminuria and renal hypertrophy in diabetes mellitus. Study in vasopressindeficient Brattleboro rats. Proc. Nat. Acad. Sci. USA. 1999, 96, 10397-10402.